Treatment of Osteoarthritis by Intra-articular Injection of Bone Marrow Mesenchymal Stem Cells With Platelet Rich Plasma
NCT ID: NCT02365142
Last Updated: 2017-10-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1/PHASE2
38 participants
INTERVENTIONAL
2014-06-30
2018-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Patients and methods
Clinical trial phase I- II, randomized , multicenter , with two treatment arms and 19 patients for each group. The investigators compare the intraarticular injection of against the administration of two different doses of mesenchymal stem cells with hialuronic acid according to the following scheme:
1. Group A: 3 intra-articular injections of platelet rich plasma (PRGF®) separated by 7 days.
2. Group B: 3 intra-articular injections of platelet richa plasma (PRGF®) separated by 7 days and one with Mesenchimal stems cells. Intra-articular injection of 100 million autologous mesenchymal progenitor stem cells cultured ex - vivo (cell suspension sterile small volume (5-10 ml ) in a vehicle suitable for intraarticular injection ) followed by an intraarticular injection of platelet richa plasma (PRGF®). The treatment is completed with 2 more injection of platelet richa plasma (PRGF®) separeted by one week.
In addition the investigators assess the response to intra-articular infusion of CMM analyzing the following parameters:
* Clinical assessment of pain and function (Baseline, 1, 3, 6 and 12 months since treatment): VAS , WOMAC , KOOS , EuroQol, SF-16, Lequesne , WOMAC , KOOS.
* Radiographic (baseline and 12 months from treatment): Femorotibial space.
* Radiographic using MRI (baseline and 12 months from treatment): by assessing the number location of the lesions , cartilage thickness , signal intensity , subchondral bone alteration , volume and WORMS and dGEMRIC protocols.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients and methods
Clinical trial phase I- II, randomized , multicenter , with two treatment arms and 19 patients for each group. The investigators compare the intraarticular injection of against the administration of two different doses of mesenchymal stem cells with hialuronic acid according to the following scheme:
1. Group A: 3 intra-articular injections of platelet richa plasma (PRGF®) separated by 7 days.
2. Group B: 3 intra-articular injections of platelet richa plasma (PRGF®) separated by 7 days and one with Mesenchimal stem cell. Intra-articular injection of 100 million autologous mesenchymal progenitor stem cells cultured ex - vivo (cell suspension sterile small volume (5-10 ml ) in a vehicle suitable for intraarticular injection ) followed by an intraarticular injection of platelet richa plasma (PRGF®). The treatment is completed with 2 more injection of platelet richa plasma (PRGF®) separeted by one week.
The autologous mesenchymal stem cells are obtained from the iliac crest under local anesthesia and sedation. They are cultured ex vivo The primary endpoint is safety and feasibility. The investigators registered the occurrence of complications and / or adverse effects during the study.
In addition the investigators assess the response to intra-articular infusion of CMM analyzing the following parameters:
* Clinical assessment of pain and function (Baseline, 1, 3, 6 and 12 months since treatment): VAS , WOMAC , KOOS , EuroQol, SF-16, Lequesne , WOMAC , KOOS.
* Radiographic (baseline, 6 and 12 months since treatment): Femorotibial space.
* Radiographic using MRI (baseline, 6 and 12 months since treatment): by assessing the number location of the lesions , cartilage thickness , signal intensity , subchondral bone alteration , volume and WORMS and dGEMRIC protocols.
All patients met the following inclusion and exclusion criteria:
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Platelet Rich Plasma (PRGF)
Platelet Rich plasma (PRGF) 3 intraarticular onjections sepataded by 7 days.
Platelet Rich plasma (PRGF)
3 injections of PRGF
BMMSC with Platelet Rich Plasma (PRGF)
Single intraarticular injection of 100 million Bone marrow mesenchimal stem cells and three intraarticular injections of plateler Rich Plasma (PRGF) separatede by 7 days.
100 million Bone marrow mesenchimal stem cells
100 million Bone marrow mesenchimal stem cells with PRGF
Platelet Rich plasma (PRGF)
3 injections of PRGF
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
100 million Bone marrow mesenchimal stem cells
100 million Bone marrow mesenchimal stem cells with PRGF
Platelet Rich plasma (PRGF)
3 injections of PRGF
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Bad results with previous hyaluronic acid injection
* Diagnosis of knee OA according to the criteria of osteoarthritis of the ACR (American College of Rheumatology)
* Joint pain equal or greater than 2.5 points on the visual analogue scale (VAS)
* Radiological Classification: Kellgren-Lawrence scale greater or equal to 2
* Body mass index between 20 and 35 kg/m2
* Ability to follow during the study period
Exclusion Criteria
* Previous diagnosis of polyarticular disease
* Severe mechanical deformation
* Arthroscopy during the previous 6 months
* Intraarticular infiltration of hyaluronic acid in the last 6 months
* Systemic autoimmune rheumatic disease
* Poorly controlled diabetes mellitus
* Blood dyscrasias
* Immunosuppressive or anticoagulant treatments
* Treatment with corticosteroids in the 3 months prior to inclusion in the study
* NSAID therapy within 15 days prior to inclusion in the study
* Patients with a history of allergy to penicillin or streptomycin
40 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Clinica Universidad de Navarra, Universidad de Navarra
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
José Lamo-Espinosa, MD
Role: PRINCIPAL_INVESTIGATOR
Clinica Universidad de Navarra
Felipe Prosper, MD, PhD
Role: STUDY_DIRECTOR
Clínica Universidad de Navarra
Juan Blanco, MD; PhD
Role: PRINCIPAL_INVESTIGATOR
Complejo Universitario de Salamanca
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Universitario de Salamanca
Salamanca, Castille and León, Spain
Departamento Cirugía Ortopédica y Traumatología. Clinica Universidad de Navarra
Pamplona, Navarre, Spain
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Lamo-Espinosa JM, Blanco JF, Sanchez M, Moreno V, Granero-Molto F, Sanchez-Guijo F, Crespo-Cullel I, Mora G, San Vicente DD, Pompei-Fernandez O, Aquerreta JD, Nunez-Cordoba JM, Vitoria Sola M, Valenti-Azcarate A, Andreu EJ, Del Consuelo Del Canizo M, Valenti-Nin JR, Prosper F. Phase II multicenter randomized controlled clinical trial on the efficacy of intra-articular injection of autologous bone marrow mesenchymal stem cells with platelet rich plasma for the treatment of knee osteoarthritis. J Transl Med. 2020 Sep 18;18(1):356. doi: 10.1186/s12967-020-02530-6.
Related Links
Access external resources that provide additional context or updates about the study.
University clinic of navarre trial information
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2011-006036-23
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
CMM-PRGF/ART
Identifier Type: -
Identifier Source: org_study_id